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Original articlea-Melanocyte stimulating hormone promotes
muscle glucose uptake via melanocortin 5
receptorsPablo J. Enriori 1,11, Weiyi Chen 1,11, Maria C. Garcia-Rudaz 1,9, Bernadette E. Grayson 2,10, Anne E. Evans 2,
Sarah M. Comstock 2, Ursel Gebhardt 3, Hermann L. Müller 3, Thomas Reinehr 4, Belinda A. Henry 1,
Russell D. Brown 1, Clinton R. Bruce 1, Stephanie E. Simonds 1, Sara A. Litwak 1, Sean L. McGee 5,
Serge Luquet 6, Sarah Martinez 6, Martin Jastroch 7, Matthias H. Tschöp 7, Matthew J. Watt 1, Iain J. Clarke 1,
Christian L. Roth 8, Kevin L. Grove 2, Michael A. Cowley 1,*ABSTRACT
Objective: Central melanocortin pathways are well-established regulators of energy balance. However, scant data exist about the role of
systemic melanocortin peptides. We set out to determine if peripheral a-melanocyte stimulating hormone (a-MSH) plays a role in glucose
homeostasis and tested the hypothesis that the pituitary is able to sense a physiological increase in circulating glucose and responds by secreting
a-MSH.
Methods: We established glucose-stimulated a-MSH secretion using humans, non-human primates, and mouse models. Continuous a-MSH
infusions were performed during glucose tolerance tests and hyperinsulinemic-euglycemic clamps to evaluate the systemic effect of a-MSH in
glucose regulation. Complementary ex vivo and in vitro techniques were employed to delineate the direct action of a-MSH via the melanocortin 5
receptor (MC5R)ePKA axis in skeletal muscles. Combined treatment of non-selective/selective phosphodiesterase inhibitor and a-MSH was
adopted to restore glucose tolerance in obese mice.
Results: Here we demonstrate that pituitary secretion of a-MSH is increased by glucose. Peripheral a-MSH increases temperature in skeletal
muscles, acts directly on soleus and gastrocnemius muscles to signiﬁcantly increase glucose uptake, and enhances whole-body glucose
clearance via the activation of muscle MC5R and protein kinase A. These actions are absent in obese mice, accompanied by a blunting of a-MSH-
induced cAMP levels in skeletal muscles of obese mice. Both selective and non-selective phosphodiesterase inhibition restores a-MSH induced
skeletal muscle glucose uptake and improves glucose disposal in obese mice.
Conclusion: These data describe a novel endocrine circuit that modulates glucose homeostasis by pituitary a-MSH, which increases muscle
glucose uptake and thermogenesis through the activation of a MC5R-PKA-pathway, which is disrupted in obesity.
 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Proopiomelanocortin (POMC) cells are found in the arcuate nucleus of
the hypothalamus (ARH), the nucleus of the solitary tract, the pituitary,
and the skin (keratinocytes). These cells produce the polypeptide
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www.molecularmetabolism.comsmaller, active peptides [1]. The POMC system within the brain is
important in the regulation of food intake and energy expenditure [2].
The pituitary gland consists of an anterior lobe (AL), an intermediate
lobe (IL), and a neural lobe (NL). Within the AL, corticotrophs express
POMC, which is processed to produce adrenocorticotropic hormone
(ACTH) and minor amounts of b-lipotrophin, b-endorphin (b-end), andustralia 2Division Neuroscience, Oregon Health and Science University, Oregon,
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Original articlea-MSH. In the IL, the predominant products are b-end and a-MSH
[3,4]. Accordingly, the predominance of circulating a-MSH originates
from the IL in most mammals. In the human, however, the IL is
rudimentary and most of the circulating a-MSH presumably originates
from the AL [3].
Our current understanding of the pituitary indicates that POMC pituitary
cells are controlled entirely by the hypothalamic endocrine system and
by feedback signals from hypothalamic circuits, the pituitary and
speciﬁc peripheral organs.
However, it is plausible that direct regulation of AL pituitary cells by
blood glucose exists, because glucose-sensing cells are found in the
AL of the pituitary [5]. In addition, peripheral a-MSH has been impli-
cated in fatty acid oxidation in skeletal muscle cells through the
activation of MC5R [6]. Since then, the peripheral effect of a-MSH has
not been tested in vivo.
Genetic defects resulting in inactivation of the central and peripheral
melanocortin system have been shown to lead to obesity and alteration
of glucose homeostasis/insulin sensitivity [7e9]. While most believe
this alteration is due to regulation by the CNS, one cannot exclude
contributions by tissues of the periphery, especially since a-MSH is
detectable in blood and its levels can change depending on different
energy states [10,11]. Skeletal muscle plays a major role in deter-
mining whole body energy expenditure, accounting for w30% of
resting energy expenditure [12]. Skeletal muscle accounts for 15e
20% total glucose disposal in the basal state and 80% under eugly-
cemic hyperinsulinemic conditions [13,14].
We set out to determine if peripheral a-MSH plays a role in glucose
homeostasis and tested the hypothesis that the pituitary is able toA
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secreting a-MSH. We show that glucose stimulates a-MSH production
and increases circulating concentrations, which increases muscle
glucose uptake through the activation of the MC5R-PKA pathway.
2. RESULTS
2.1. Postprandial a-MSH release
To begin, we employed RIA to speciﬁcally detect and quantify a-MSH
levels in the plasma after a meal. We found that a-MSH levels in the
plasma of rhesus macaques ﬂuctuate between a 5e25 pM range
during a 24-h fasting period. With scheduled feeding of a standard
low-fat diet, a-MSH levels increased by 2-fold above fasting levels
(AUC p < 0.05, Figure 1A and B). To determine the relationship be-
tween a-MSH release and diet composition, animals received a high
caloric diet (HCD), a standard diet (control diet), or no meal after an
overnight fast. Caloric intake was higher in the group fed with HCD
(2020  378 vs 941  70 cal) and, as shown in Figure 1C, a-MSH
levels were signiﬁcantly increased to 33.3  5.7 pM (p < 0.001) after
5 h of HCD feeding compared to 5 h fasting, suggesting that speciﬁc
components of this diet induced a release of a-MSH into the blood.
2.1.1. a-MSH release from the pituitary is regulated by glucose
Following the postprandial release of a-MSH, we determined the
source of a-MSH by assessing a-MSH expression using double
immuno-ﬂuorescence with anti-a-MSH/ACTH in Japanese macaque
pituitary samples (Figure 2B). A cross-reaction was avoided by pre-
absorbing the anti-a-MSH antibody with ACTH and vice versaB
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(Figures 2C and S1). Most of the AL cells were ACTH positive, while
some showed co-localization with a-MSH. In contrast, most of the IL
cells were double-positive for a-MSH and ACTH. Interestingly, some
tightly arranged cells in the IL were observed with high a-MSH
immunoreactivity (1300 pmol/mg protein). Additionally, the AL
contributed considerably to the a-MSH levels detected (650 pmol/mg
protein) (Figure 2A and D).
To bolster the above ﬁndings, we investigated a-MSH levels in patients
with low- or non-functioning pituitaries, panhypopituitarism (PH), and
in patients with craniopharyngioma after surgery (CP). We established
that both PH and CP patients had very low plasma a-MSH levels, being
70% lower than healthy subjects with intact pituitary function
(Figure 2E). Moreover, plasma a-MSH levels were undetectable (the
sensitivity of radioimmunoassay is 0.30 fmol/mL) in about half of the
patients, and measurements could be obtained in all healthy controls.
Thus far, these results strongly support the pituitary as the main
contributor of circulating a-MSH and bring to light a plausible role of a-
MSH in glucose regulation.
2.1.2. Glucose regulates circulating a-MSH levels in humans,
monkeys and mice
Before delving into the role of a-MSH in glucose regulation, we per-
formed glucose tolerance tests (GTT) in healthy and obese children
(oral), lean and obese monkeys (intravenous, iv), and lean and diet
induced obese (DIO) mice (intraperitoneal, ip) to examine a-MSH
regulation by glucose in vivo. As shown in Figure 3A, B, and C, a-MSHA
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Figure 2: The pituitary is the source of a-MSH, and its secretion is regulated by glucose. A
lobe, IL: intermediate lobe, PL: posterior lobe. Samples were taken from areas depicted in
(red) and ACTH (green) expression. C. CDI of single-label immunoﬂuorescence for a-MSH (r
localized a-MSH/ACTH expressing cells and some cells only expressing ACTH. D. a-MSH
(n ¼ 3). E. Plasma a-MSH levels in healthy humans (H, n ¼ 27), patients with hypopitu
***p < 0.001 vs. healthy controls by one-way ANOVA followed by Bonferroni’s Test. Dat
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However, in monkeys, we observed an initial smaller a-MSH peak
(5 min), which likely resulted from iv administration causing a far more
rapid delivery of glucose to the peripheral tissues. Obese subjects
displayed the same pattern of a-MSH response as lean controls
(Figure 3A). Obese monkeys had a higher response of a-MSH than
controls (Figure 3B). Additionally, we estimated a strong correlation
between a-MSH with both blood glucose and plasma insulin levels
(AUC, Figures S3A and S3B), supporting the hypothesis that glucose
and/or insulin regulate a-MSH in vivo. Since ACTH is co-localized with
ɑ-MSH in human corticotroph cells, we tested whether ɑ-MSH
secretion could occur independently of ACTH co-release. We did not
ﬁnd any change in ACTH levels after glucose administration in either
lean or obese humans (Figure 3A). To further ascertain whether the
levels of a-MSH were augmented by the direct effect of glucose, we
compared the levels of a-MSH after ip glucose or saline administration
in lean mice. We found a signiﬁcant peak of a-MSH at 15 min
(66.8 pM, p < 0.01) after the glucose challenge and no changes after
saline injection (Figure 3D). To establish whether this response
was due to POMC cell activation, we studied mice with disrupted KATP
channel function in POMC cells (POMC-mutKir6.2 mice) [15].
These mice exhibited no change in a-MSH secretion in response to
glucose administration (Figure 3E). Altogether, these results strongly
support the hypothesis that pituitary POMC cells are responsible for
sensing the plasma glucose ﬂuctuations, which, in turn, stimulates a-
MSH secretion.C
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Figure 3: Glucose increases levels of plasma a-MSH, but not ACTH, in humans, monkeys, and mice. A. a-MSH levels and ACTH levels during an OGTT in normal body weight
(control) and obese children (n ¼ 6). B. a-MSH levels during an ivGTT in control and obese S-HFD Japanese macaques (n ¼ 5). C. a-MSH levels during an ip GTT in control and
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Original article2.1.3. Systemic a-MSH increases glucose clearance
Next, we probed the role of systemic a-MSH in glucose regulation. To
achieve that, we ﬁrst conducted a short-term systemic a-MSH
infusion in lean mice and found that it did not modify glucose levels in
fasted condition (Figure S4A). We then monitored glucose excursions
during ip GTT’s in mice that received either a 3 h saline or a-MSH
infusion. We treated lean mice with a series of a-MSH doses ranging
from 0.0005 mg/h to 1 mg/h and found a signiﬁcant improvement in
glucose tolerance at a dose of 0.001 mg/h a-MSH, which corresponds
to 90 pM of a-MSH in blood (Figure 4A and C). We did not ﬁnd any
further improvement in glucose tolerance using higher doses of a-810 MOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. ThMSH (Figures 4A and S5A). In separate experiments, using a recently
validated technique [16], we conﬁrmed that a-MSH infusion
increased whole-body 2-deoxy-D-[1-14C]glucose (2DG) clearance
(Figures S4C and D). In spite of enhanced glucose tolerance, the
insulin levels were not statistically lower in a-MSH treated animals
compared with saline treated mice (Figure S4B), supporting the
premise that the main effect of a-MSH was on glucose disposal in
skeletal muscle.
To prove this notion, we employed hyperinsulinemic-euglycemic clamp
to reveal any tissue-speciﬁc regulation of a-MSH on glucose
homeostasis (Figure S6A). Of note, body weight, blood glucoseis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: a-MSH infusion in lean mice enhances glucose clearance by increasing muscle glucose uptake in vivo. Very low plasma a-MSH level is associated with glucose
intolerance. AeB. Area under curve of GTT and plasma a-MSH levels during 3 h saline/a-MSH infusion using different doses of a-MSH (n ¼ 4e14). C. Systemic a-MSH infusion
(1 mg/h) increases glucose disposal during ip GTT in lean mice, (**p < 0.01, ***p < 0.001 vs. saline infusion, n ¼ 6e9). D. a-MSH increases glucose infusion rate in lean mice
during a 2 h hyperinsulinemic-euglycemic clamp (n ¼ 7). E. a-MSH increases GIR during steady state. F. Systemic a-MSH increases insulin-mediated and whole body glucose
disposal rate without altering basal Rd. G. Under clamp conditions, a-MSH enhances glucose uptake into soleus and gastrocnemius muscle but not into other metabolically active
tissues. H. Hepatic glucose production remains unchanged between saline and a-MSH treated group. I. Post-prandial muscle temperature after systemic a-MSH infusion (external
jugular vein, 100 mg/h) or saline in sheep. J. Post-prandial muscle temperature after direct a-MSH infusion (1 mg/h) or saline into the femoral artery. A datalogger was surgically
inserted into the vastus lateralis muscle of sheep to read temperature at 150 intervals (n ¼ 4). Grey box represents food availability (11:00 to 16:00 h). p < 0.01 by AUC analysis.
Data are expressed as mean  SEM. *p < 0.05, **p < 0.01 saline vs. a-MSH. See also Figures S4, S5 and S6concentrations, and insulin levels were equivalent between saline and
a-MSH treated mice (Figure S6BeS6D). During the hyperinsulinemic-
euglycemic clamp, mice treated with a-MSH required higher glucose
infusion rate to maintain normal glucose levels (Figure 4D and E).
Interestingly, these mice also displayed a marked increase in insulin-
mediated and whole body glucose disposal, which brought forward an
additive effect of a-MSH in glucose clearance under clamp condition
(Figure 4F). Moreover, increased glucose uptake was signiﬁcant inMOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comskeletal muscles, in particular the soleus and the gastrocnemius
muscle as opposed to other metabolically active tissues such as kid-
ney, adipose tissues and heart (Figure 4G). Importantly, endogenous
hepatic glucose production (HGP) did not differ between both groups,
which revealed a direct action of a-MSH on skeletal muscle
(Figure 4H). No further effect of a-MSH on the liver was observed as
evidenced by quantitative RT-PCR of gluconeogenic enzymes after
clamp or systemic infusion studies (Figure S6E). In addition, ween access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 811
Original articlevalidated the direct effect of exogenous a-MSH on muscle by using an
established model of diet-induced entrainment of a thermogenic
response in sheep [17]. We found that systemic a-MSH infusion
increased post-prandial muscle temperature in sheep (Figure 4I).
Furthermore, a-MSH infusion into the leg femoral artery resulted in an
increase in muscle temperature, while we were unable to measure
changes on the contra-lateral saline infused site (Figure 4J), further
demonstrating a direct effect of a-MSH on skeletal muscle. Together,
these data suggest that a-MSH acts directly on skeletal muscle to
increase glucose clearance and thermogenesis and this effect is in-
dependent of hepatic glucose production.
2.1.4. a-MSH increases glucose uptake in skeletal muscle
To determine if the effect of a-MSH on skeletal muscles was direct, we
took an ex vivo and in vitro approach. During these studies, it became
evident that a-MSH increased basal glucose disposal in a dose-
responsive manner (Figure S7). Furthermore, data from ex vivo 2-DG
uptake of isolated soleus displayed an enhancement of 2-DG uptake
induced by a-MSH on top of insulin-mediated 2-DG uptake (Figure 5A).
Similar results were observed in cultured myotubes (GLUT4myc-L6)
(Figure 5B). Using the cultured myotubes, we also measured the ox-
ygen consumption rate (OCR) and the extracellular acidiﬁcation rate
(ECAR, assessing glycolysis) applying an extracellular ﬂux analyzer
system (Seahorse). We detected a dose-dependent increase of
glycolysis induced by a-MSH (Figure 5C), without a concomitant
change in OCR (data not shown), indicating that the main short-term
action of a-MSH is through glycolysis and not increased mitochon-
drial respiration. Interestingly, we also found that culturing L6 myo-
tubes in high concentrations of glucose (25 mM) blocked a-MSH
induced glycolysis (Figure S7). To this end, these results are in
agreement with the concept that a-MSH acts directly on skeletal
muscles to regulate glucose homeostasis.
2.1.5. MC5R is crucial for peripheral a-MSH action in muscle
To ensure that the effect observed was not confounded by any possible
actions in the CNS, we repeated the a-MSH infusion after blocking
brain melanocortin receptors (MC3/MC4R) with icv injection of their
endogenous antagonist, AgRP. We established a dose of AgRP
(1.0 nmol) that completely abolished the anorectic effect of MTII
(Figure S10A), thereby demonstrating complete blockade of the MC3/
MC4R. We found that this blockade did not prevent the a-MSH
mediated improvements in glucose tolerance (Figure 6A). In a separate
experiment, we corroborated the role of peripheral a-MSH on glucose
homeostasis by administering lean mice with neutralizing antibodies
against a-MSH through the tail vein (iv) or the lateral ventricle (icv).
Lean mice were rendered glucose intolerant when neutralizing anti-
bodies against a-MSH were given systemically as opposed to icv
antibody treatment (Figure S10B). This is supported by a signiﬁcant
increase in blood glucose levels during a GTT compared to mice that
received puriﬁed rabbit IgG as control (Figure 6B). Notably, the anti-
bodies did not impact basal glycemia (antibody treated: 8.5  1.3 vs
saline treated: 8.6  1.6 mmol/l, respectively). Strikingly, POMC-
mutKir6.2 mice (with no change in a-MSH secretion in response to
glucose administration) were found to be glucose intolerant
(Figures S9A and B), supporting the premise that a-MSH from the
pituitary acts upon skeletal muscle to regulate glucose homeostasis in
response to glucose load. To mechanistically delineate the action of a-
MSH on skeletal muscle, we ﬁrst assessed which melanocortin re-
ceptor (MCR) subtypes were expressed in skeletal muscle. Out of all
the different subtypes of melanocortin receptors, we found that only
MC5R was highly expressed in skeletal muscles of both lean and DIO812 MOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. Thmice (Figures 6C and D and S10C, S10D). Going further, we investi-
gated whether MC5R mediates the action of a-MSH by using PG-901,
which is a human and mouse MC5R speciﬁc agonist and a neutral
antagonist of human and mouse MC3/4R [18,19]. Short-term incu-
bation of PG-901 increased glucose uptake in GLUT4myc-L6 myotubes
(Figure S11). Following that, we performed similar in vivo infusion and
GTT studies to assess glucose disposal in mice lacking MC5R (MC5R
KO) [20]. As shown in Figure 6E, there were no differences in glucose
tolerance between a-MSH and saline infused MC5R KO mice. On the
contrary, glucose tolerance was signiﬁcantly enhanced by a-MSH
infusion in wild-type littermates. In addition, a-MSH-mediated glucose
disposal was completely abrogated in the isolated skeletal muscle of
MC5R KO mice (Figure 6F). Furthermore, lean mice given highly se-
lective MC5R antagonist [21] ip displayed signiﬁcantly higher glucose
levels relative to the saline group (Figure 6G). Interestingly, MC5R KO
mice showed hyperinsulinemia when fasted and 30 min after glucose
administration (Figure 6H), suggesting that MC5R KO mice compen-
sate for the lack of a-MSH with an increase of insulin to restore
euglycemia. These results illustrated that MC5R plays a vital role in
mediating glucose clearance in skeletal muscle upon binding to a-
MSH.
2.1.6. A combined therapy of nonselective/selective
phosphodiesterase 4 inhibitor and a-MSH ameliorates glucose
intolerance in obese mice
In healthy individuals, blood glucose is tightly regulated; however, a
prominent feature of diet-induced obesity is glucose dysregulation and
the eventual development of type 2 diabetes. Therefore, to examine the
therapeutic relevance of a-MSH-mediated glucose disposal, we next
probed the effect of a-MSH in mice fed with HFD. Intriguingly, we did
not ﬁnd any improvement in glucose tolerance in DIO mice (Figure 7A).
In line with the in vivo ﬁnding, neither a-MSH nor insulin increased
glucose disposal in isolated soleus muscle obtained from DIO mice,
which highlighted an insulin resistant and possibly a a-MSH resistant
phenotype in these mice (Figure 7B). Since melanocortin receptors are
members of 7-transmembrance G protein-coupled receptor (GPCR),
MC5R couples to stimulatory G protein alpha upon ligand binding,
which classically increases cyclic adenosine monophosphate (cAMP)
production and PKA activity [22]. We next measured cAMP levels in the
soleus muscle of lean and DIO mice that received a-MSH infusion
during a glucose challenge. We found that cAMP levels were signiﬁ-
cantly elevated in lean mice in contrast with DIO mice where the effect
was abrogated (Figure 7C). In addition, selective inhibition of PKA by
H89 in L6 cells revealed that the activation of PKA was necessary for
a-MSH-mediated glucose uptake (Figure 7D).
Further, we measured phosphodiesterase (PDE) protein levels in
muscles from lean and DIO mice to inquire whether the failure of a-
MSH to induce glucose uptake in obesity was associated with the
inability to increase cAMP. Interestingly, we found a higher expression
of PDE4B in obese compared to lean mice (Figure 7E and F). Based on
this result, we next isolated soleus muscles from DIO mice and per-
formed an ex vivo incubation with theophylline, a non-selective PDE
inhibitor, together with a-MSH. The inhibition of PDEs in the presence
of a-MSH was able to restore glucose uptake in muscles from DIO
mice (Figure 7G). To test the physiological relevance of combined PDE
inhibition and a-MSH in vivo, we pretreated mice with theophylline for
5 days prior to a-MSH infusion. Of note, theophylline treatment did not
modify basal glucose levels, but it signiﬁcantly improved glucose
tolerance in obese mice (AUC p < 0.01) (Figure 7H). We also pre-
treated mice with rolipram, which selectively inhibits PDE4, particularly
the PDE4B isoform [23]. Rolipram pretreatment for 5 days prior to a-is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: a-MSH increases glucose uptake and glycolysis in ex vivo skeletal muscle and differentiated L6-cells. A. a-MSH increases glucose uptake in soleus muscles from
control mice (n ¼ 8). Muscles were incubated with Insulin 10 nM, a-MSH 100 nM for 200. Radioactivity was measured in muscle lysates by liquid scintillation counting. B. a-MSH
increases glucose uptake in differentiated L6-cells and potentiate insulin action. Each bar represents an average from 3 independent experiments, n ¼ 3 in each one. Cells were
preincubated with a-MSH for 1 h before starting the glucose uptake. Radiolabeled 2-deoxy-D-[2,6-3H]glucose (1 mmol/l, 0.5 mCi/ml), 10 nM insulin, 100 nM a-MSH or both was
added to the corresponding well and maintained for 150. C. Glycolysis time-course (as extracellular acidiﬁcation rate; ECAR) was measured by Seahorse analyzer from a-MSH (1e
100 nM, *p < 0.05 and **p < 0.01 vs. basal). Data are expressed as mean  SEM. See also Figures S7 and S8MSH infusion signiﬁcantly improved glucose disposal during GTT in
obese mice (AUC p< 0.05) (Figure 7I). Surprisingly, we did not ﬁnd an
improvement in glucose tolerance in DIO mice with either theophylline
or rolipram alone (Figure 7H and I). Hence, this suggests that sub-
chronic treatment of phosphodiesterases alone is not sufﬁcient to
reverse glucose intolerance; however, it is able to potentiate a-MSH-
mediated glucose disposal to restore glucose tolerance in DIO mice.
Collectively, our results strongly support a novel model where pe-
ripheral a-MSH regulates glucose homeostasis by acting via MC5R-
cAMP-PKA pathways in skeletal muscle.
3. DISCUSSION
3.1. Feeding and glucose increase a-MSH secretion
These studies describe a new endocrine circuit that is capable of
modulating post-prandial glucose homeostasis. Our studies showed
that a-MSH levels have a prandial pattern of secretion increasing after
meal consumption. Furthermore, a-MSH peaks occurred after con-
sumption of a HCD, suggesting that diet composition inﬂuences the
physiological release of a-MSH. We observed in humans, non-human
primates, and mice that a-MSH levels consistently increased in
response to plasma glucose excursions, suggesting glucose is a
regulator of plasma a-MSH. In accordance with the presence of
glucose-sensing cells within the pituitary AL [5], we found an increase
in a-MSH release from isolated pituitaries incubated with glucose.
Moreover, mice lacking pituitary glucose-sensing capacity (POMC
mutKir6.2) [15] displayed glucose intolerance, which further sub-
stantiates the hypothesis that the pituitary senses and reacts to
changes in glucose homeostasis. This could be explained in part by theMOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comlarge reduction (w70%) in plasma a-MSH levels in HP and CP pa-
tients. These ﬁndings also demonstrate that the pituitary melanocortin-
secreting cells utilize a beta-cell-like mechanism to couple extracel-
lular glucose levels to hormone secretion. Importantly, the activity of
the HPA axis did not change during a GTT, as was previously
demonstrated [24], suggesting that the increase in ɑ-MSH secretion is
a speciﬁc effect of glucose-mediated processing/secretion of ɑ-MSH
from pituitary cells.
3.2. Circulating a-MSH is secreted from the pituitary
There is a preponderance of data supporting the production of a-MSH
by pituitary cells and extrapituitary cells, such as keratinocytes,
monocytes, astrocytes, gastrointestinal and the brain [25]. Here, we
showed that a substantial amount of a-MSH in the blood (w70%) was
produced by the pituitary in higher mammals. This ﬁnding was
demonstrated by in vitro studies determining a-MSH secretion from
dissected areas of the pituitary and by measuring a-MSH levels in
patients with normal, low- or non-functioning pituitaries.
While in rodents the IL is anatomically well-deﬁned, in adult humans
and non-human primates, it is a rudimentary structure along the
border of the anterior and neural lobes consisting of a small number of
POMC-synthesizing cells [26,27]. In line with other reports, we showed
that AL and IL cells are capable of producing a-MSH in human and
non-human primate adult pituitary [3,28,29]. In addition, patients with
acute phase septic shock or untreated Addison disease displayed
elevated a-MSH levels [30,31].
POMC-derived peptides such as ACTH, as well as a-, b-, and g-MSH,
exert their pleiotropic effects via binding to MCRs at different binding
afﬁnity and potency. In the present study, we focus exclusively on theen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 813
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Figure 6: Peripheral a-MSH acts via the MC5R to increase glucose disposal in vivo. A. Blockade of MC3/MC4R with icv AgRP (1.0 nmol, 1 ml) prior to a-MSH infusion cannot
prevent the increase of glucose disposal during GTT (n ¼ 4) (#p < 0.05 vs. icv aCSF þ infusion a-MSH, **p < 0.01, ***p < 0.001 vs. icv AgRP þ infusion a-MSH). The dose AgRP
was selected from a cumulative food intake experiment (Figure S4E). B. Neutralizing a-MSH IgG reduces glucose disposal during a GTT (*p < 0.05 and **p < 0.01 vs. IgG control).
Mice received an iv injection of anti a-MSH (20 mg/ml) or rabbit IgG (n ¼ 9). GTT was performed 900 after injection. C. MC5R expression was not different in soleus muscles from
lean and DIO mice (n ¼ 4e5). D. Quantiﬁcation of MC5R measured by Western blot as a ratio of a/b tubulin. E. Systemic a-MSH infusion does not increases glucose disposal
during ip GTT in MC5R KO mice (n ¼ 6e14). *p < 0.01 and ***p < 0.001 by two-way ANOVA followed by Bonferroni’s Test for each group vs littermate a-MSH infusion group. F.
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way ANOVA followed by Bonferroni’s Test. See also Figures S9, S10 and S11
Original articlerole of a-MSH on glucose homeostasis using a highly speciﬁc radio-
immunoassay plasma a-MSH that was previously described [32,33].
Noteworthy, the assay has no cross-reactivity with ACTH and b-, and
g-MSH (by standard displacement curve) so the a-MSH detected in814 MOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. Ththis study is not a degradation product of ACTH [32]; a-MSH has an
identical amino acid sequence to the residues of ACTH (1e13) and a-
MSH levels overlap with ACTH levels. Consistent with the literature, we
found that ACTH levels were not altered following overnight fasting [34]is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 7: Inhibition of PDE’s enhances the effect a-MSH on glucose disposal in DIO mice. A. Systemic a-MSH infusion did not increase glucose disposal in DIO mice (n ¼ 8). B.
Insulin and a-MSH-mediated glucose uptake was abrogated in ex vivo soleus extracted from DIO mice (n ¼ 5). C. Systemic a-MSH infusion (1 mg/h) increases cAMP levels in
muscles of lean mice instead of DIO mice (n ¼ 5e7). cAMP concentration was measured after 45’of initiating a-MSH infusion and 250 of starting GTT. D. a-MSH (100 nM)
increases glucose uptake in differentiated L6-cells, and it is inhibited by pretreatment with a selective inhibitor of cAMP dependent protein kinase (15 mM H89 during 300).
##p < 0.01 vs control, ***p < 0.001 vs H89. E. PDE4B expression in soleus muscle was higher in DIO mice than lean mice in basal conditions (n ¼ 4e5). F. Quantiﬁcation of
PDE4B measured by Western blot as a ratio of beactin (*p < 0.05 vs. lean). G. a-MSH (100 nM) increases glucose uptake in soleus muscles from DIO mice after a preincubation
with a non-selective PDE inhibitor (Theophylline; 100 uM) for 20’. **p < 0.01 vs. basal baseline by one-way ANOVA followed by Bonferroni’s Test. H. Pre-treatment with daily ip
theophylline (20 mg/kg) for 5 days before systemic a-MSH infusion (1 mg/h) increases glucose disposal during ip GTT in DIO mice (n ¼ 7). As a control, mice were pre-treated with
the correspondent vehicle (DMSO 50%). ***p < 0.001 vs. Theophylline þ a-MSH, £p < 0.05 and £££p < 0.001 vs. vehicle þ a-MSH, #p < 0.05 and ##p < 0.01 vs.
theophylline þ saline by two-way ANOVA followed by Bonferroni’s Test. I. Pre-treatment with ip Rolipram (5 mg/kg) two times daily for a period of 5 days before systemic a-MSH
infusion (1 mg/h) increases glucose disposal during ip GTT in DIO mice (n ¼ 8e9). It was compared to DIO mice receiving saline infusion. The systemic a-MSH infusion and
posterior GTT was exactly as described in Figure 4. Data are expressed as mean  SEM. *p < 0.05 and ***p < 0.001 vs. rolipram þ a-MSH, £££p < 0.001 vs. vehicle þ a-MSH,
#p < 0.05 and ##p < 0.01 vs. rolipram þ saline by two-way ANOVA followed by Bonferroni’s Test.
MOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original articleand during OGTT in humans [35,36]. Thus the peptides described as
a-MSH here are speciﬁcally a-MSH levels.
3.3. Physiological levels of a-MSH increase glucose tolerance and
muscle glucose uptake
The indication that peripheral a-MSH has a role in glucose homeo-
stasis came from the ﬁnding that the infusion of a-MSH increases
glucose tolerance during a GTT in lean mice. Importantly, these results
were obtained using doses of a-MSH within the physiological range.
Moreover, this effect was speciﬁc to a-MSH as mice display reduced
glucose tolerance during GTT after systemic administration of a-MSH
neutralizing antibody. Studies have documented that central activation
of MCRs play a role in skeletal muscle glucose uptake [37,38]. Con-
trary to our results, blockade of brain MC3/MC4R could not prevent the
increase in glucose tolerance after a glucose challenge during a-MSH
infusion. In fact, the response observed in mice was partly at a cellular
level given that a-MSH stimulated glucose uptake in soleus and
gastrocnemius muscle biopsies extracted from lean mice in our ex vivo
studies. Further, during hyperinsulinemic-euglycemic clamp, we
showed that the addition of a-MSH enhanced glucose clearance
through soleus and gastrocnemius muscles without altering hepatic
glucose production and gluconeogenic enzymes expression in the
process, further bolstering the action of a-MSH on skeletal muscle. To
our knowledge, this is the ﬁrst evidence of the direct action of a-MSH
on skeletal muscle to regulate glucose homeostasis.
While insulin is the principal regulator of glucose homeostasis, we
believe that pituitary a-MSH plays a modulatory role in postprandial
regulation of blood glucose, but is not a substitute for insulin.
Interestingly, POMC homozygous null mice showed a normal
response to GTT [39] and, recently, a rare case of human with
complete POMC deﬁciency and type 1 diabetes was described; the
patient had insulin requirements appropriate for his age and pu-
bertal development [40]. It seems that the lack of POMC (a-MSH) in
both models is not enough to modify the glucose homeostasis. In
contrast, we found that POMC-mutKir6.2 mice had very low plasma
a-MSH levels and were unable to increase a-MSH secretion in
response to glucose administration. In addition, POMC-mutKir6.2
mice are glucose intolerant, which highlights the importance of
a-MSH in the regulation of glucose homeostasis. Moreover, the fact
that MC5R KO mice, which are not obese, require a higher level of
insulin to maintain a normal glucose homeostasis support the idea
that a-MSH integrates a complementary endocrine circuit that
regulates postprandial glucose homeostasis, mainly through the
increases muscle glucose intake via a different pathway to insulin.
Data regarding the potential correlation of plasma a-MSH with in-
sulin resistance/obesity is conﬂicting. While some studies showed
that plasma a-MSH levels correlated with insulin resistance/obesity
in humans [10,11], others claimed that these were unrelated to
body composition [31,41]. Our results are in agreement with the
latter, as we did not observe any relationship between plasma a-
MSH levels and body weight or HOMA (an index of insulin resis-
tance) in any of the species analyzed.
Several studies have addressed the role of circulating a-MSH in the
regulation of energy homeostasis [9,42,43] mainly focusing on fat
metabolism and thermal regulation [42] but not on glucose regulation.
Intriguingly, An et al. showed that a-MSH enhances glucose uptake
stimulated by insulin in the C2Cl2 mouse muscle cell line. However,
data regarding the effect of a-MSH alone on glucose uptake are
lacking in this study [6]. Further, we showed that a-MSH increases
glycolysis in L6 muscle cells and induces anaerobic respiration to
produce ATP and lactic acid. Moreover, the increase in muscle816 MOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. Thtemperature of the sheep suggests a local and direct action of a-MSH
on femoral muscle after a-MSH artery infusion. Altogether these
results indicate that a-MSH induces energy consumption in the
muscle.
In addition, the extracellular ﬂux data indicate incomplete glucose
oxidation, and this may explain why the effect is only seen in glycolytic
muscle (Gastrocnemius vs. soleus muscle). Of note, our data do not
exclude glycogen production in muscle. We did not ﬁnd any changes in
mitochondrial respiration and FAO in L6 cells incubated with a-MSH as
described by An et al. in both C2C12 myotubes and primary muscle
cells [6], Instead, we found a doseeresponse increase in glycolysis
after incubation with a-MSH. The discrepancy could be due to the use
of different cell lines to determine FAO and the methodology employed
in this study. However, we cannot exclude the increase in FAO in
response to a-MSH infusion in vivo.
3.4. MC5 R and cAMP mediate the action of a-MSH on glucose
tolerance and muscle glucose uptake
Five MCR subtypes have been described [2,22]. We conﬁrmed that
only MC5R was highly expressed in skeletal muscle [44]. This receptor
has been previously implicated in water repulsion, pheromone
secretion, and regulation of several exocrine glands [20,45]. Inter-
estingly, a recent human study showed that single-nucleotide poly-
morphism in the MC5R was associated with type 2 diabetes in obese
subjects [46]. MC5R is ubiquitously expressed in peripheral tissues,
and it is similar to the MC1R and MC4R in its capacity to recognize a-
MSH and ACTH but not g-MSH (b-MSH is not produced in rodents).
Thus, it is possible that other melanocortins besides a-MSH can
participate in the mechanisms described above. However, neither their
physiological relevance nor their postprandial secretion patterns is
known.
MC4R has been extensively studied, and it has a critical role in the
central control of metabolism. However, our studies ruled out a role
for central melanocortins using CNS blockade of melanocortin re-
ceptors and using MC5R agonist PG-901 as an antagonist at MC4R. It
has also been demonstrated that genetic background has a modifying
effect on the phenotype of MC4R KO mice. The MC3R has a clear
metabolic phenotype, and this manuscript describes an important
role of MC5R in modulation of glucose homeostasis in muscle [47e
49]. Therefore, the role of peripheral melanocortin system in regu-
lating glucose metabolism should receive more attention and further
investigation.
In our ex vivo and in vivo studies presented here, the effect of glucose
uptake or glucose disposal driven by a-MSH was completed blunted in
MC5R KO mice. Additionally, we showed that speciﬁc inhibition using
MC5R selective antagonist caused a similar reduction in glucose
tolerance in lean mice to that of a-MSH neutralizing antibody, sug-
gesting that MC5R is essential to mediate the action of a-MSH in the
periphery. This ﬁnding also put forward a tonic role of a-MSH on MC5R
during basal condition as blockade of MC5R results in hyperglycemia
during GTT in these mice. Collectively, these results corroborated the
crucial role of MC5R in regulating glucose homeostasis.
MCRs couple to stimulatory G protein to increase cAMP production in
response to receptor activation. However, activation also involves
several other cAMP independent pathways [50]. We found that a-MSH
increases cAMP levels in the muscle of lean mice during GTT. Most of
the published studies showed that an increase of cAMP subsequently
enhances the activity of PKA. However, it has been recently demon-
strated that cAMP can mediate glucose uptake in smooth muscle
independently of PKA activation [51]. We discovered that the activation
of PKA is necessary for a-MSH mediating glucose uptake because pre-is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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incubation of L6 muscle cells with a potent selective PKA inhibitor
(H89) abolished the effect of a-MSH. In our recent study, Møller et al.
reported that a-MSH stimulated phosphorylation of short isoform of
TBC1D1 but not TBC1D4 (also called AS160) in soleus muscle (PLoS
One, in press); two related Rab-GTPase activating proteins that are
involved in the translocation of GLUTs in response to insulin/exercise
[52]. GLUT12 seems to be a likely candidate to be responsible for a-
MSH-mediated glucose uptake as it accounts for 12% of insulin-
induced glucose transporters translocation in humans muscles [53].
However, additional studies are required to identify which glucose
transporter is involved as Møller et al. did not observe a change in
GLUT4 translocation upon a-MSH stimulation in cultured myocytes
(PLoS One, in press).
3.5. Blockade of phosphodiesterases restores a-MSH mediated
glucose uptake to muscle from obese mice
Throughout this study, a-MSH has consistently failed to produce any
effect associated with glucose homeostasis under obese/hyperglyce-
mic conditions. Indeed, a-MSH did not modify the glucose tolerance
during GTT in obese mice, did not increase glucose uptake in isolated
muscles from DIO mice, and did not drive glycolysis in cells cultured in
high glucose.
The fact that MC5R expression was similar in lean and DIO mice
suggests that the failure of a-MSH to induce glucose uptake in hy-
perglycemic subjects was not due to the lack of receptor. In addition,
cAMP levels in the muscle of obese mice were unaltered after a-MSH
treatment indicating the failure of signal transduction. Furthermore,
PDE expression was higher in the muscle of DIO mice, suggesting that
the blunted response in cAMP activation in DIO mice could be due
PDEs inactivating cAMP [54].
Interestingly, by blocking PDE activity with theophylline, a non-
selective PDEs inhibitor, we were able to restore a-MSH-mediated
glucose uptake in isolated muscles from obese mice. More impor-
tantly, we found that both selective and non-selective PDE4B inhibition
with rolipram and theophylline, respectively, were able to enhance the
effect of a-MSH infusion and signiﬁcantly improve the glucose toler-
ance during GTT in obese mice. Restoration of this mechanism in the
obese could potentially open new avenues to adjunctive pharmaco-
logical treatments to reduce postprandial glucose excursions. It was
recently shown that another PDE4 inhibitor roﬂumilast reduced gly-
cosylated hemoglobin and post-meal glucose in a trial in type 2 di-
abetics [55], although the mechanism of the effect was not
determined. Our work suggests that PDE4 inhibitors should be further
investigated in type 2 diabetes and perhaps in combination with a-
MSH.
3.6. Limitations
The fact that the MC5R KO mice are not diabetic seems to question the
role of MC5R in glucose metabolism. Although they appear metabol-
ically normal, MC5R KO mice are hyperinsulinemic at baseline state
and after a glucose load. These mice required twice the level of insulin
relative to their wildtype littermates at baseline and at the peak of a
GTT to maintain a normal glucose tolerance, suggesting an increase in
insulin secretion to compensate for a lack of a-MSH action via MC5R
on muscle. The phenomenon of compensation in KO mice is not un-
usual. For example, despite the strong pharmacological evidence
supporting the role of NPY and AgRP in energy balance a conventional
knockout of either NPY or AGRP results in normal body weight,
adiposity, and food intake. On the contrary, postnatal genetic ablation
of AgRP neurons leads to hypophagia and starvation [56]. These ob-
servations further demonstrate that there are inherent limitations inMOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comapproaches using mice that develop while either lacking or over-
expressing key proteins of interest.
In conclusion, we have discovered a novel endocrine circuit that reg-
ulates postprandial glucose homeostasis. These results demonstrate
that in humans, non-human primates, and mice, the pituitary detects
circulating glucose and responds with increased a-MSH secretion.
Overall, this is the ﬁrst report showing that the increase in plasma a-
MSH exclusively enhances muscle glucose uptake through the direct
activation of canonical MC5R-PKA pathways in muscle of lean but not
obese subjects; inhibition of phosphodiesterase restores a-MSH
mediated glucose tolerance in obese mice. Our discovery provides the
basis for future studies to determine how melanocortin control of
muscle glucose uptake and glycolysis can be utilized in treating pa-
tients with obesity and type 2 diabetes.
4. EXPERIMENTAL PROCEDURES
4.1. Subjects and patients
Twenty-seven normal weight children (15 girls/12 boys, mean age
10 y) and 39 obese children (20 girls/19 boys, mean age 11 y) were
studied. In a subgroup of obese (otherwise healthy) and normal weight
children (n ¼ 6/per group) an oral GTT (1.75 g/kg, max. 75 g) was
performed. a-MSH, insulin and glucose were determined at time
points (00, 150, 300, 600 and 1200). Inclusion criteria were normal
weight or obese male or female children age 6e16 years old.
Exclusion criteria were current endocrine disorders or intake of pre-
scription medications. In addition, ﬁfteen patients with craniophar-
yngioma (CP) (mean age 13.8 y) and 4 Hypopituitarism (HP) patients
were studied. In most CP patients, hypothalamic involvement,
assessed by intraoperative microscopic inspection and/or imaging,
was present. Three quarters of patients received percutaneous cranial
irradiation because of incomplete resection.
4.2. Hypopituitarism patients
Two patients had no lesion as shown by MRI and presented with GH
and TSH deﬁciency and GH, TSH, and ACTH deﬁciency, respectively.
The other two patients had panhypopituitarism secondary to cranio-
pharyngioma treatment and presented both with combined GH, ACTH,
gonadotropin, and TSH and ADH deﬁciency.
4.3. Monkey model and experiments
For spontaneous secretion of a-MSH: Eight male rhesus macaques
10e18 years-old were studied in an environment controlled for hu-
midity, temperature, and lighting (7:00 ame7:00 pm) at the Oregon
National Primate Research Center (ONPRC). Animals were fed 12
biscuits (control monkey diet) (#5047, jumbo size; Purina) at 9:00 am
and again at 3:00 pm. Biscuits had an energy density of 3.11 kcal/g
(25% protein, 5% fat and 57.5% CH). Monkeys were catheterized as
described previously [57] for remote collection of blood samples
(hourly during 24 h) and placed in on a control diet or fasted for 24 h.
In a subsequent study, blood sampling was performed either at
baseline (3:00 pm after a morning fast) or at 8:00 pm after ad libitum
consumption of control diet (n ¼ 6), High caloric diet (HCD, n ¼ 6), or
fasting (n¼ 6). A HCD consisting of semi-solid cubes weighingw60 g
with an energy density of 3.9 kcal/g (20% protein, 35% fat, and 45%
carbohydrate) was provided as noted during speciﬁc experiments.
Drinking water was continuously available via pressurized drinking
spouts.
For ivGTT we studied a model of obese Japanese macaque monkeys
that was described in detail elsewhere [58]. Age and weight-matched
young adult female Japanese macaque (ages 5e7 y and weight 7een access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 817
Original article9 kg) were placed on either a standard monkey chow that provide 14%
calories from fat (Monkey Diet # 5052; Lab Diet) or a HFD that supplied
32% calories from fat plus calorically dense treats (Custom Diet 5A1F;
Test Diet) and followed over 3 years. During the 3rd year of HFD, ﬁve of
nine monkeys showed a signiﬁcant increase in body weight (sensitive
to HFD) while the other 4 had normal weights (resistant to HFD).
Monkeys were tested after an overnight fast. Glucose (0.6 g/kg; 50%
dextrose solution) was administered by continuous infusion over 1 min
via the small saphenous vein. Blood samples were obtained before and
after infusion via the femoral artery (1, 3, 5, 10, 20, 40 and 60 min).
Glucose was measured using an OneTouch Ultra Blood Glucose
Monitor (LifeScan).
Three pituitaries were dissected under microscopy to obtain AL and IL.
Tissues sections were collected in 2N acetic acid and processed to
measured a-MSH content as previously published [33].
4.4. Immunohistochemistry
Four Japanese macaques were ﬁxative perfused in 4% buffered
paraformaldehyde and the pituitary harvested and parafﬁn embedded.
Pituitary was cut at 5 mm. Standard IHC methods were used. Detail for
this method is provided in the Supplementary methods.
Monkey procedures were performed in accordance with the guidelines
and approval of the Oregon National Primate Research Center’s
Institutional Animal Care and Use Committee.
4.5. Mouse models and experiments
At 5e6 wk of age, C57BL/6J mice (Monash Animal Services) were fed
a regular rodent diet (Specialty Feeds) or a HFD (SF04-001; Specialty
Feeds) for 20 wk, as previously described [33]. POMC-mutKIR6.2 and
MC5R KO mice and their respective wildtype littermates were fed a
regular diet for 15e20 wk. Mice were housed (5/cage) in a controlled
environment, but they were individually caged during each experiment.
Food and water were available ad libitum. Body weights were
measured weekly. All procedures were performed in accordance with
the guidelines and approval of the Monash University Animal Ethics
Committee.
4.6. Glucose tolerance test and insulin tolerance test
Glucose tolerance test (GTT) and insulin tolerance test (ITT) were
performed as previously described [33]. For GTT, blood samples were
obtained after 4 h fast, at 0, 15, 30, 60 and 120 min post glucose
challenge. For MC5R KO mice, blood samples (w50 ml) were collected
from the saphenous vein at 0 and 30 min after a glucose challenge for
the measurement of insulin.
4.7. a-MSH infusion
Mice were instrumented with an arterial catheter (carotid artery) to
monitor blood pressure and for sample collection. At the same time, a
venous catheter (jugular vein) was placed to infuse a-MSH. The doses
infused were 0.0005, 0.00075, 0.001, 0.01, 0.1, and 1 mg/h for 3 h.
Blood glucose was measured before and at 100 and 200 of a-MSH
infusion. After that, mice received an ip glucose injection (GTT, 1 mg/
g). Blood glucose levels were measured at 150, 300, 600 and 120 min
after glucose challenge. Some mice were sacriﬁced at time 45 min to
perform studies in skeletal muscle, liver and blood.
4.8. a-MSH infusion with pre-treatment of theophylline
Mice were instrumented with a venous catheter and received daily ip
injection of theophylline (20 mg/kg) for 5 days or vehicle (DMSO 50%).
Then a-MSH (1 mg/h) was infused and GTT performed as above.818 MOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. Th4.9. a-MSH infusion with pre-treatment of rolipram
Mice received ip Rolipram (5 mg/kg) or vehicle (DMSO 5%) two times
daily for a period of 5 days. Then a-MSH (1 mg/h) was infused and GTT
performed as above.
4.10. Hyperinsulinemiceeuglycemic clamp
Mice were subjected to jugular vein catheterization 5 days prior to
hyperinsulinemic euglycemic clamp studies. Mice were anesthetized
with isoﬂurane (2e3% in oxygen) while an indwelling silastic catheter
was inserted into the right internal jugular vein and exteriorized
through the back of the neck. The catheters were kept patent with
heparin sodium (10 IU/ml, Pﬁzer) and sealed with a stainless steel
plug. Mice were allowed 4e5 days postsurgical recovery. Food pellets
were placed at the bottom of the cage to facilitate recovery. Body
weight was recorded daily, and mice that had less than 5% weight loss
were subsequently studied.
Hyperinsulinemic euglycemic clamps were performed on 6 h fasted,
conscious, and unrestrained mice. The infusion protocol consisted of
a 60 min tracer equilibration period (t¼60 to 0 min), followed by a
120 min experimental period (t ¼ 0e120 min). A bolus of [3-3H]
glucose (2.5 mCi; PerkinElmer) was administered at t ¼ 60 min,
followed by a constant infusion of 0.05 mCi/min for 60 min, starting
at 0900 h. At t ¼ 15 and 5 min, blood samples (w50 ml)
were obtained from a small nick in the tail vein for the assessment of
basal plasma glucose concentration, plasma insulin, and glucose-
speciﬁc activity. At 1000 h, hyperinsulinemic, euglycemic clamp
was initiated at t ¼ 0 min with an infusion of human insulin (4 mU/
kg/min; ActRapid; Novo Nordisk). To minimize changes in glucose
speciﬁc activity, the continuous infusion of high-pressure liquid
chromatography-puriﬁed [3-3H]glucose was increased to 0.1 mCi/
min and maintained throughout the procedure. Blood glucose was
measured every 5 min, and 30% dextrose (3 g of D(þ)-Glucose in
10 ml of saline, Merck) was infused at variable rates to maintain
euglycemia (w6.5e7.5 mmol/L). Blood samples (10 ml) were taken
every 10 min from t ¼ 90e120 min to determine glucose-speciﬁc
activity. At the end of the clamp procedure, mice were anes-
thetized with sodium pentobarbital (60 mg/kg), tissues were
extracted within minutes and stored in 80 C for later analysis.
Plasma insulin was determined from samples obtained from cardiac
puncture.
4.11. Determination of plasma and tissue radioactivity
Blood samples (10 ml) were deproteinized with equal molar volume
(0.3N) of barium hydroxide and zinc sulfate. [3-3H]glucose radioactivity
in the supernatant was assessed by liquid scintillation counting. Whole
body glucose kinetics, such as the rate of glucose appearance
(endogenous Ra) and disappearance (Rd), were calculated using iso-
topic steady-state equations of Steel. Endogenous glucose production
during the clamp was calculated by subtracting the glucose infusion
rate (GIR) from whole body Rd. The insulin-stimulated component of the
Rd (IS-Rd) is equal to clamp Rd minus the basal glucose turnover rate. 2
[14C]DG radioactivity was determined by liquid scintillation counting.
Soleus, extensor digitorum longus, gastrocnemius, kidney, WAT, BAT,
and heart lysates were processed through ion-exchange chromatog-
raphy columns (Poly-Prep Preﬁlled Chromatography Columns, AG1-X8
resin, 100e200 mesh dry; Bio-Rad) to separate 2DG from 2DG-6-
phosphate (2DG6P). The area under the tracer disappearance curve
of [14C]2DG and the radioactivity for the phosphorylated [14C]2DG from
individual tissues were used to calculate the glucose metabolic index
(Rg0).is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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4.12. Blockade of MC4R by AgRP
Mice were cannulated for icv injections as described previously [33].
One hour before the start of saline or a-MSH infusion, AgRP (1.0 nmol,
1 ml) or aCSF (1 ml) was injected into the lateral ventricle. The dose of
AgRP was selected from pilot experiments, which showed that
1.0 nmol of icv AgRP(83-132) completely blocked the anorectic effect
of 1.0 nmol of MTII (a high afﬁnity melanocortin receptor agonist) when
is injected 1 h before MTII. A similar dose (0.2e1.0 nmol) was used
previously to block central MC3/4 receptors [59].
4.13. Passive administration of polyclonal neutralizing a-MSH IgG
Mice fed a regular diet were matched in their weight and in their
glucose values during GTT. After 3 h of fasting, mice received an iv
injection of 200 ml of anti a-MSH (20 mg/ml, Sigma). This concen-
tration corresponds to 100 times molar excess to of normal a-MSH
levels in humans (w50 pM), This quantity of antibody is able to bind
100% of a-MSH in circulation as was previously demonstrated to
neutralizing others peptides [60]. Ninety min after antibody injection,
basal glucose was measured and GTT was performed as described. As
a control, a group of mice was injected with an equal amount of pu-
riﬁed rabbit IgG (Zymed, Life technologies). To evaluate a potential
nonspeciﬁc effect of the antibody on glucose levels, a week before the
immunoneutralization experiment, mice received an iv injection of
200 ml of saline and glucose levels were measured. Another group of
mice were cannulated for icv injections and anti a-MSH (10 mg/ml,
1 ml) or puriﬁed rabbit IgG (1 ml) was injected into the lateral ventricle.
The speciﬁcity of injected antibodies were evaluated by incubation of
serum from the mice treated either with anti a-MSH or rabbit IgG with
125I-a-MSH.
4.14. Passive administration of MC5R antagonist
A highly selective and potent MC5R antagonist was synthesized ac-
cording to the structure (Peptide code 5) previously published [21].
After an overnight fast, mice received an intraperitoneal injection of
either saline or MC5R antagonist (4 nmol/l, 100 ml) 15 min before
glucose challenge.
4.15. a-MSH immunoassay
In plasma and tissues were measured by an in-house radioimmuno-
assay using a rabbit anti-a-MSH (#M0939). In previous publications,
we validated this RIA to use in human, non-human primates and
mouse plasma [32,33]. Brieﬂy, considering that a-MSH is a trideca-
peptide with an amino acids sequence that is identical to residues 1e
13 of ACTH and that only differs in the N-terminal acetyl and C-terminal
valine-amide, we performed a displacement technique to test the cross
reactivity of the anti-a-MSH antibody with ACTH. We found that the
anti-a-MSH antibody cannot detect ACTH in the concentration studied
(10e100 pg/ml). Similarly to ACTH, we did not ﬁnd any cross reaction
between a-MSH and b-and g-MSH [33]. Furthermore, to demonstrate
that a-MSH detected in plasma is not a degradation product of ACTH,
we added ACTH to human pool of plasma and endogenous a-MSH and
ACTH, which was measured during 24 h at 25 C. Although ACTH
degraded at room temperature no increase of a-MSH as a degradation
product was detected [32].
4.16. ACTH immunoassay
Plasma ACTH levels were measured by a commercially available IRMA
(IRMA ACTH, Mitsubishi Kagaku Iatron, Inc, Tokyo, Japan) as was
previously described [32]. According to manufacturer, the antibody
does not cross react with a-MSH, or ACTH 1-24, but it can detect
human and rat ACTH 1-39.MOLECULAR METABOLISM 5 (2016) 807e822  2016 The Author(s). Published by Elsevier GmbH. This is an op
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All values are expressed as mean  SEM. Group mean differences
were assessed using Student’s unpaired t-test when two groups were
compared. AUC was calculated by trapezoid analysis and was
compared by t-test. Data were analyzed by one-way or two-way
analysis of variance (ANOVA) followed by Bonferroni’s multiple-
comparison post hoc test when more of two groups were compared
or for time courses or dose response studies. Correlation was analyzed
by linear regression analysis. p < 0.05 was considered statistically
signiﬁcant. Analyses were performed with GraphPad Prism 6.0
(GraphPad Software, Inc.).
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